In January 2006, the U.S. Food and Drug Administration (FDA) approved a new antianginal agent for the treatment of chronic stable angina, ranolazine (Ranexa™; CV Therapeutics, Inc.). The drug, ...

New American guidelines for chronic coronary disease (CCD) modify management considerations for a heterogeneous group that includes people with or without angina, a history of coronary ...

Ranolazine is an antianginal drug and a class V antiarrhythmic drug that is mainly used for the treatment of chronic angina. Ranolazine is also used off-label to treat certain arrhythmias, including ...

WAYNE, Pa.--(BUSINESS WIRE)--XyloCor Therapeutics, a clinical-stage biopharmaceutical company developing novel gene therapies for cardiovascular disease, today announced completion of the Phase 2 ...

SUNNYVALE, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, ...

WAYNE, PA.--(BUSINESS WIRE)--XyloCor Therapeutics, Inc., a clinical‑stage biopharmaceutical company developing novel gene therapies for cardiovascular disease, today presented results from the Phase 2 ...

Depression can occur in approximately 1 in 5 patients who have chronic stable angina. After diagnosis of chronic stable angina, depression can occur in approximately 1 in 5 patients, according to a ...

The biopharmaceutical company behind a gene therapy designed to help patients with chronic angina by prompting the growth of new blood vessels in the heart said recent trial results have shown ...

Causes of chest pain, some benign and some serious, include heart attack, angina, heartburn, infections, inflammation, and panic attacks. If you experience new chest pain, it's best to seek medical ...

Most patients with coronary artery disease (CAD) and chronic stable angina will obtain complete relief of symptoms with percutaneous coronary intervention (PCI). However, some chronic angina patients ...